CD163 and the FVIII/FXII ratio identified as novel biomarkers for early sepsis recognition

Key Points

• Early sepsis recognition can be enhanced by using CD163 and FVIII/FXII ratio as biomarkers.
• The study highlights the importance of identifying biomarkers in improving clinical recognition of sepsis.
• Assessing CD163 and FVIII/FXII ratio could lead to timely interventions for sepsis.
• The findings may indicate a new path for advancing sepsis diagnostics in clinical settings.

Abstract